Are there common biochemical and molecular mechanisms controlling manganism and parkisonism.
Over the past several decades there has been considerable progress in our basic knowledge as to the mechanisms and factors regulating Mn toxicity. The disorder known as manganism is associated with the preferential accumulation of Mn in the globus pallidus of the basal ganglia which is generally considered to be the major and initial site of injury. Because the area of the CNS comprising the basal ganglia is very complex and dependent on the precise function and balance of several neurotransmitters, it is not surprising that symptoms of manganism often overlap with that of Parkinson's disease. The fact that neurological symptoms and onset of Mn toxicity are quite broad and can vary unpredictably probably reflects specific genetic variance of the physiological and biochemical makeup within the basal ganglia in any individual. Differences in response to Mn overexposure are, thus, likely due to underlying genetic variability which ultimately presents in deviations in both susceptibility as well as the characteristics of the neurological lesions and symptoms expressed. Although chronic exposure to Mn is not the initial causative agent provoking Parkinsonism, there is evidence suggesting that persistent exposure can predispose an individual to acquire dystonic movements associated with Parkinson's disease. As noted in this review, there appears to be common threads between the two disorders, as mutations in the genes, parkin and ATP13A2, associated with early onset of Parkinsonism, may also predispose an individual to develop Mn toxicity. Mutations in both genes appear to effect transport of Mn into the cell. These genetic difference coupled with additional environmental or nutritional factors must also be considered as contributing to the severity and onset of manganism.
Roth
Jerome A
JA
Department of Pharmacology and Toxicology, University at Buffalo, 11 Cary Hall, Buffalo, NY, 14228, USA. jaroth@buffalo.edu
D000818:Animals; D027682:Cation Transport Proteins / Q000737:chemistry / Q000235:genetics / Q000633:toxicity; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005917:Globus Pallidus / Q000737:chemistry / Q000187:drug effects; D006801:Humans; D007501:Iron / Q000737:chemistry / Q000378:metabolism; D008345:Manganese / Q000378:metabolism / Q000633:toxicity*; D020149:Manganese Poisoning / Q000150:complications / Q000235:genetics* / Q000473:pathology; D051379:Mice; D009784:Occupational Diseases / Q000139:chemically induced / Q000235:genetics* / Q000473:pathology; D016273:Occupational Exposure; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000235:genetics* / Q000473:pathology; D006180:Proton-Translocating ATPases / Q000235:genetics; D051381:Rats; D044767:Ubiquitin-Protein Ligases / Q000235:genetics; D000099236:Solute Carrier Family 11, Member 2
D027682:Cation Transport Proteins; D007501:Iron; D008345:Manganese; D006180:Proton-Translocating ATPases; D044767:Ubiquitin-Protein Ligases; D000099236:Solute Carrier Family 11, Member 2; C514983:ATP13A2 protein, human; C111567:parkin protein